Stock Market Reviews

Read and share opinions on SKYE (Skye Bioscience, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
  Nov 13, 2025
• Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...
  Nov 11, 2025
• Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
  Nov 5, 2025
• Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
  Nov 5, 2025
• Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next
  Oct 7, 2025
• Top Midday Decliners
  Oct 6, 2025
• Could This New Drug Be The Safer Way To Fight Obesity?
  Sep 19, 2025
• Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
  Sep 19, 2025
• Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
  Sep 4, 2025
• Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
  Sep 2, 2025
• Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
  Aug 27, 2025
• Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
  Aug 21, 2025
• Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...
  Aug 8, 2025
• Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
  Aug 7, 2025
• We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully
  Aug 5, 2025
• Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
  Jul 30, 2025
• Skye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a Data
  Jul 6, 2025